Silver Book Fact

Cost-savings associated with Warfarin use in AFib patients

Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.

Mercaldi, CJ, M Ciaramentaro, B Hahn, G Chalissery, MW Reynolds, SD Sander, GP Samsa, and DB Matchar. Cost Efficiency of Anticoagulation with Warfarin to Prevent Stroke in Medicare Beneficiaries with Nonvalvular Atrial Fibrillation. Stroke. 2011; 42(1): 112-8. http://stroke.ahajournals.org/cgi/content/short/42/1/112

Reference

Title
Cost Efficiency of Anticoagulation with Warfarin to Prevent Stroke in Medicare Beneficiaries with Nonvalvular Atrial Fibrillation
Publication
Stroke
Publication Date
2011
Authors
Mercaldi, CJ, M Ciaramentaro, B Hahn, G Chalissery, MW Reynolds, SD Sander, GP Samsa, and DB Matchar
Volume & Issue
Volume 42, Issue 1
Pages
112-8
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Identifying individuals at high risk for developing AFib
    Using simple bedside measures, identification of individuals at risk for developing atrial fibrillation is feasible. Selecting high-risk individuals for inclusion in atrial fibrillation prevention trials may also enhance prevention strategies.  
  • Effects of optimal anticoagulation among AFib patients
    If 50% of individuals with atrial fibrillation who do not receive prophylaxis were optimally anti-coagulated, 19,380 emboli would be prevented and $1.1 billion would be saved each year.  
  • Catheter ablation reduces risk of stroke and death among AFib patients
    Atrial fibrillation patients who underwent catheter ablation had a reduced risk of stroke and death—2.2% of those who had ablation experienced stroke versus 4.7% on medications alone, and 6% died from…  
  • AFib practice guidelines reduce direct health care costs
    The use of practice guidelines in atrial fibrillation (AF) patients significantly decreased hospitalization and resource utilization—with an average decrease in 30-day total direct health care costs of around $1,400 per patient.  
  • Stroke prevention through optimal anticoagulation
    If half of atrial fibrillation patients who currently receive warfarin in a routine care setting had their anti-coagulation optimized, around 9,000 strokes and more than 29,000 bleeds would be prevented.